Clinical Trials

51 enrolled

Breast Neoplasms

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

70 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

25 enrolled

Urinary Bladder Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT05567835 2026-02-23

TOGAR

3 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Triple Negative Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07402473 2026-02-11

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT01932697 2026-02-10

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

81 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT04884282 2026-02-06

COMBI-TED

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04340882 2026-01-30

DoceRamPem

30 enrolled

Lung Neoplasms

NCT07214987 2026-01-30

PDT For Induction Therapy For Head And Neck Cancer

26 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

17 enrolled

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

40 enrolled 12 charts

Prostatic Neoplasms

NCT04095689 2026-01-23

INTEGRAL

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

60 enrolled

Hormone Sensitive Prostate Cancer

NCT03456843 2026-01-21

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

190 enrolled

Stage IV Prostate Adenocarcinoma AJCC v7

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT07354984 2026-01-21

PIONEER-HN

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

14 enrolled 16 charts

Prostatic Neoplasms

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Salivary Gland Neoplasms

NCT07330050 2026-01-09

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

31 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT04367311 2026-01-02

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

100 enrolled

Lung Neoplasms

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

128 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT07268794 2025-12-08

CONVERT-HB1

112 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

188 enrolled

Breast Neoplasms

NCT05027633 2025-11-19

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT04386746 2025-11-17

GEMDOCE

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

10 enrolled 17 charts

Lung Neoplasms

NCT04329065 2025-11-06

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

25 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05541016 2025-11-04

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

455 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT05057247 2025-10-31

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

26 enrolled 23 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07220135 2025-10-23

NeoTHERa

100 enrolled

Breast Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

4 enrolled 11 charts